Verubecestat and Lanabecestat are well-studied BACE-1 inhibitors in animals and have proven their effectiveness in mild to moderate AD patients, such as reduction in soluble Aβ in CSF, significantly [150,151]. Here, BACE1 is linked to Alzheimer disease.